Effects of Atosiban on clinical outcomes of in vitro fertilization-embryo transfer

Conditions

infertility

He Cai, Shan Liu, Wentao Li, Haiyan Bai, Hanying Zhou et al. (23 authors)

Human Reproduction2025-02-28

O-029 Atosiban in women with previous single implantation failure undergoing frozen-thawed blastocyst transfer: a placebo-controlled randomized trial

He Cai, Su Liu, Chiu‐Yueh Yang, L Chen, Jian Xie et al. (10 authors)

Human Reproduction2024-07-01

10.1093/humrep/deae108.029

Effectiveness of atosiban in women with previous single implantation failure undergoing frozen-thawed blastocyst transfer: study protocol for a randomised controlled trial

He Cai, Shan Liu, Lijuan Chen, Jinlin Xie, Chen Yang et al. (8 authors)

BMJ Open2023-10-014 citations

10.1136/bmjopen-2023-076390

Interventions

Experimental group:atosiban

Control group:placebo

Eligibility

Sex/Gender

Female

Age

20 Years to 38 Years

Inclusion criteria

Inclusion criteria: 1. IVF and ICSI women and consent to participate in this study and sign informed consent; 2. Transplantation of fresh or frozen blastocysts failed only once; 3. Single blastocyst transfer (HRT cycle); 4. Endometrial thickness (> 7mm) on HCG day in fresh cycle; 5. Aged between 20 and 38 years old; 6. BMI (< 28) (kg/m2).

Exclusion criteria

Exclusion criteria: 1. severe endocrine disorders (such as hyperthyroidism, hypothyroidism, hyperprolactinemia, etc.) and other systemic diseases (such as hypertension, diabetes, etc.); 2. severe uterine malformations, uterine fibroids and untreated hydrosalpinx were excluded; 3. recurrent miscarrage; 4. severe endometriosis (Ems III or IV); 5. PGS patients; 6. known allergic history of Atoxiban; 7. Participate in other RCT experiments.

Design outcomes

Primary

Measure	Time frame
live birth rate;	—

Countries

China

Contacts

Public ContactLiu Shan

Northwest Women's and Children's Hospital

123564787@qq.com+86 189 9193 2450

Outcome results

None listed